Key facts
- This page summarizes Frank Palantoni's Form 4 filing for LEXICON PHARMACEUTICALS, INC. (LXRX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 22 May 2023, 16:06.
Frank Palantoni - 21 May 2023 Form 4 Insider Report for LEXICON PHARMACEUTICALS, INC. (LXRX)
- Reporting relationship
- Director
- Issuer ticker
- LXRX
- Reported as of
- 21 May 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 May 2023, 16:06:07 UTC
- Prior SEC filing
- 28 Apr 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frank P. Palantoni
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Frank Palantoni filed Form 4 for LEXICON PHARMACEUTICALS, INC. (LXRX) on 22 May 2023.
Change
- Previous filing in this sequence was filed on 28 Apr 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
LXRX
transaction
Common Stock
Options Exercise
- Transaction value
- $0
- Shares
- +9,302
- Change %
- +30%
- Price
- $0.000000
- Shares after
- 40,332
- Date
- 21 May 2023
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LXRX
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,302
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 21 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 9,302
- Exercise price
- $0.000000
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Restricted stock unit vests with respect to 100% of the shares subject to the restricted stock unit on the first anniversary of the grant date.
Footnote F2
Each restricted stock unit represents a contingent right to receive one share of common stock.